Trial Profile
Phase 1 Study of Elotuzumab in Combination With Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Elotuzumab (Primary) ; Lenalidomide (Primary) ; Dexamethasone; Diphenhydramine; Diphenhydramine; Paracetamol; Ranitidine
- Indications Multiple myeloma
- Focus Adverse reactions
- 04 Jun 2019 Results assessing addition of elotuzumab and autologous peripheral blood mononuclear cell (PBMC) reconstitution to standard-of-care autologous hematopoietic stem cell transplantation and lenalidomide maintenance, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 15 Aug 2017 Status changed from recruiting to completed.